Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

PARS:US

0.0695 USD 0.0195 39.00%

As of 20:10:00 ET on 04/17/2015.

Snapshot for Pharmos Corp (PARS)

Open: 0.0700 Day's Range: 0.0695 - 0.0700 Volume: 12,000
Previous Close: 0.0500 52wk Range: 0.0330 - 0.3100 1-Yr Rtn: -13.13%

Stock Chart for PARS

No chart data available.
  • PARS:US 0.0700
  • 1D
  • 1M
  • 1Y
0.0500
Interactive PARS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PARS

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -0.0400
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 4.18
Shares Outstanding (M) 60.17
30 Day Average Volume 10,828
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PARS

No data available

Company Profile & Key Executives for PARS

Pharmos Corporation is a bio-pharmaceutical company that discovers and develops new drugs to treat a range of neuroinflammatory disorders. The company has a portfolio of drug candidates under development. Pharmos's main product, dexanabinol, is a synthetic non-psychotropic cannabinoid currently in late stage clinical development for the treatment of traumatic brain injury (TBI).

Robert F JohnstonChairmanEric W FangmannActing President/Acting CFO
More Company Profile & Key Executives for PARS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil